SCHEMBL23749758

SCHEMBL23749758

Cc1csc(=N)n1-c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.72
MAPT P10636 3/20 0.72
RAB9A P51151 3/20 0.72
NPC1 O15118 2/20 0.72
GAA P10253 2/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
ALOX15 P16050 1/20 0.68
ALOX12 P18054 1/20 0.68
CYP1A2 P05177 1/20 0.61
CYP2C19 P33261 1/20 0.61
HSD17B10 Q99714 1/20 0.43
LMNA P02545 1/20 0.41
GSK3B P49841 4/20 0.41
GSK3A P49840 3/20 0.39
NOTUM Q6P988 1/20 0.37
MAPK1 P28482 2/20 0.36
HTT P42858 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616053 0.76 CYP1A2 (0.61) ALDH1A1MAPTRAB9ANPC1GAA
SCHEMBL15965314 0.74 EGFR (0.45) ALDH1A1MAPTRAB9ANPC1GAA
Hydrochloric Acid SCHEMBL15952788 0.73 EGFR (0.44) ALDH1A1MAPTRAB9ANPC1GAA
SCHEMBL4616637 0.72 CYP1A2 (0.56) ALDH1A1MAPTRAB9ANPC1GAA
SCHEMBL4616638 0.72 CYP1A2 (0.56) ALDH1A1MAPTRAB9ANPC1GAA
SCHEMBL23728036 0.68 CYP1A2 (0.51) ALDH1A1RAB9ANPC1GAASMN1; SMN2
SCHEMBL23728038 0.68 CYP1A2 (0.51) ALDH1A1RAB9ANPC1GAASMN1; SMN2
SCHEMBL23749756 0.68 SMN1; SMN2 (0.47) ALDH1A1MAPTRAB9ANPC1GAA
SCHEMBL25002124 0.68 HSD17B10 (0.47) ALDH1A1MAPTRAB9ANPC1GAA
SCHEMBL65301 0.68 MAPT (0.54) ALDH1A1MAPTRAB9AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 US disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 EP disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2023-05-04 US disclosed
CN-115515579-A Pyrrolo [2,3-b ] pyridine-3-carboxamide compositions and methods for ameliorating hearing loss 洛克菲勒大学 2022-12-23 CN disclosed
EP-4100008-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS The Rockefeller University (US) 2022-12-14 EP disclosed
WO-2021158936-A1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS THE ROCKEFELLER UNIVERSITY (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 ALDH1A1 2546/4885MAPT 4154/4885RAB9A 2310/4885
US-20230137893-A1 PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS LATS2, LATS1, YAP1 ALDH1A1 3775/4885MAPT 2385/4885RAB9A 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.